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Augmentation of sebum secretion by Propionibacterium acnes through an increase in 
ABCB1-mediated transporter activity in differentiated hamster sebocytes 
T Sato and N Akimoto Department of Biochemistry, Tokyo University of Pharmacy and Life 
Sciences, Hachioji, Japan
Acne vulgaris is a chronic inflammatory disease in sebaceous glands and pilosebaceous units 
where excess sebum production and secretion are observed. Propionibacterium acnes (P. acnes), a 
Gram-positive anaerobic microbial species, is considered to play a role in the aggravation of acne. 
Although P. acnes, as well as peptidoglycan (PGN) from Gram-positive bacteria, has been reported 
to potentially augment the production of sebum in hamster sebaceous glands in vivo and in vitro, 
it is not fully understood whether P. acnes participates in the regulation of sebum secretion. In the 
present study, formaldehyde-fixed P. acnes (F-Acne) was found to increase not only the extracellular 
level of triacylglycerol (TG), which is a major component of sebum, but also the transporter activity 
using Rhodamine 123 in differentiated hamster sebocytes (DHS). In addition, the F-Acne-augmented 
extracellular TG level was decreased in the presence of an ABCB1 inhibitor, PSC833. Furthermore, 
the gene expression of ABCB1 was increased in the F-Acne-treated DHS. Similar augmentation of 
ABCB1-mediated TG secretion, transporter activity, and ABCB1 gene expression were detectable 
in PGN-treated DHS. Therefore, these results put forward novel evidence that P. acnes facili-
tates ABCB1-mediated TG secretion via PGN-induced signal pathways, under which ABCB1 gene 
expression is concomitantly enhanced in DHS. Moreover, these findings should accelerate the 
understanding of sebum secretion in sebaceous glands of acne patients, and may contribute to the 
development of acne therapy.    
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Comparative activity of oral ivermectin and moxidectin in an experimental pig model of 
scabies 
C Bernigaud,1 F Fang,1 K Fischer,2 A Lespine,3 D Dreau,4 A Kelly,5 F Botterel,1 J Guillot1 
and O Chosidow6 1 Dynamyc, ENVA,UPEC, Maisons-Alfort, France, 2 QIMR Berghofer 
Medical Research Institute, Infections Diseases Dept, Brisbane, QLD, Australia, 3 INRA, 
UMR 1331,Toxalim, Toulouse, France, 4 Cecaveto, Saint-Allouestre, France, 5 Dept of 
Agriculture,Fisheries and Forestry, QD Animal Science Precinct,UQ, Gatton, QLD, Australia 
and 6 AP-HP, Henri Mondor Hospital, Dept of Dermatology,UPEC, Créteil, France
Control of human scabies is hampered by limited number of suboptimal efficient therapies. The 
aim of our study was to use pigs as an animal model for testing new drugs like veterinary molecules 
(e.g.moxidectin MOX, macrocyclic lactones) with more attractive pharmacokinetic profiles that 
common treatment (i.e oral ivermectin IVM). We conducted a blind, controlled trial comparing 
oral IVM (200 μg/kg on days 0 and 10) with oral MOX (300 μg/kg at day 0) in pigs experimentally 
infested with Sarocoptes scabiei var suis at the veterinary college of Alfort, France using a previously 
described procedure. The study was approved by the Animal Ethics Committee. Pigs received 0.2mg/
kg/d of dexamethasone to increase intensity and duration of scabies and were treated 9 weeks follow-
ing infestation. 12 pigs (in 3 groups) were randomly assigned to IVM, MOX or no treatment-group. 
Every week, therapeutic monitoring was to score skin lesions and pruritus, to count mites and eggs 
in skin scrapings, to collect skin biopsies, blood samples for pharmacokinetics analysis of drugs 
and anti-Sarcoptes antibodies. The primary outcome was the complete absence of mites on day 
14 post treatment. No adverse events were reported. The percentage reduction of mites count for 
the MOX-pigs was 50% at D2, 97.7% at D7 and 100% at D9 and 14. The percentage reduction 
of mites for the IVM-pigs was 20.7% at D2, 53.9% at D7, 95.9% at D9 and 83.4% at D14. For 
both groups, the decrease of eggs was 100%. After treatment, eggs from all three cohorts were able 
to hatch in an incubator (37°C, humidity 70%) indicating a suboptimal ovicidal activity of both 
drugs. As conclusion, a single dose of MOX seems to be effective and a promising alternative to 
the treatment of scabies.    
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Involvement of HHV-6 infection in renal damage associated with DIHS/DRESS
K Miyashita, T Shoubatake, T Nishimura, K Ogawa, F Miyagawa, N Kobayashi, R Onmori 
and H Asada Dermatology, Nara Medical University, Kashihara, Japan
Drug-induced hypersensitivity syndrome/drug reaction with eosiophila and systemic symptoms 
(DIHS/DRESS) is one of the severe drug eruption with fever, lymphadenopathy, human herpesvi-
rus 6 (HHV-6) reactivation, and multiple organ failure. Renal failure is occasionally observed in 
DIHS/DRESS patients, and affects the prognosis of the patients. However, the pathogenesis is still 
unknown. In this study, we studied the patient who developed renal failure during the course of 
DIHS/DRESS, and found that HHV-6 infection was involved in the development or triggering of 
renal failure. A 62-year-old Japanese man developed high fever, systematic erythema and bilateral 
cervical lymphadenopathies on day 28 after receiving trimethoprim/sulfamethoxazole (TMP/SMX). 
HHV-6 DNA was detected in peripheral blood mononuclear cells (PBMC) on day 21 after onset 
(2×10 copies/ml). He was diagnosed as DIHS/DRESS due to TMP/SMX. His symptoms immediately 
disappeared after the withdrawal of TMP/SMX and induction of systemic steroid therapy. However, 
he developed acute renal failure that necessitated hemodialysis on day 79 after onset. HHV-6 DNA 
was also detected in urine (2×10 copies/ml). He subsequently died from opportunistic infection 
and multiple organ failure despite intensive therapy. The autopsy examination revealed interstitial 
nephritis with an intense lymphocytic infiltrate and tubular necrosis. Viral load of HHV-6 were sig-
nificantly increased in autopsy renal specimens from this patient (8×104 copies/100mg), compared 
to specimens of other organs. Furthermore, HHV-6 antigens were detected in the tubular epithelial 
cells by immunostaining with anti-HHV-6 monoclonal antibody. This is the first biologically and 
histologically proven report on the relationship between renal failure and HHV-6 infection during 
the course of DIHS/DRESS. We considered that HHV-6 may be associated with development or 
triggering of renal failure related to DIHS/DRESS.    
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Telaprevir-induced drug eruption
E Nic Dhonncha,1 A Murad,1 S Curran,3 J Lee2 and M Laing1 1 Dermatology, University 
College Hospital, Galway, Ireland, 2 Gastroenterology, University College Hospital, Galway, 
Ireland and 3 Histopathology, University College Hospital, Galway, Ireland
Telaprevir is a protease inhibitor used in the treatment of chronic hepatitis C genotype 1 infection. 
We present four cases of telaprevir-induced skin eruption including a novel case of telaprevir-in-
duced vasculitis with a literature review. The first patient was a 61-year-old male with a two-week 
history of a generalized eczematous eruption that started on his buttocks and subsequently spread 
to involve his trunk and limbs. The rash developed seven weeks after commencing telaprevir. A 
skin biopsy showed subacute spongiotic dermatitis. The second case was a 57-year-old male who 
presented with a four-week history of a palpable purpuric rash on his legs which began eight weeks 
after starting telaprevir. Skin histology confirmed the diagnosis of cutaneous vasculitis. The third 
patient was a 50-year-old male who presented with a generalized eczematous eruption within one 
week of commencing telaprevir. The fourth and final case was a 60-year-old female who presented 
with an extensive eczematous eruption, which developed twelve weeks after commencing telapre-
vir. The patient was admitted to hospital with pancytopenia. Telaprevir was discontinued and the 
rash subsided following treatment with topical corticosteroids. All four patients were systemically 
well, with no mucous membrane involvement. All patients were treated conservatively and did not 
require systemic steroids. All eruptions gradually resolved over up to six weeks after completion 
of telaprevir treatment. Telaprevir-induced rash is the most common adverse effect associated 
with the drug, and occurs in 51% of patients. In its most severe form, patients are required to stop 
treatment. Case 2 described above highlights the awareness of a vasculitic-type rash which has not 
previously been reported in telaprevir-treated patients. A collaborative effort between dermatologists 
and hepatologists may improve the tolerability of telaprevir in patients with moderate to severe 
telaprevir-induced eruptions as demonstrated in our case series.    
466
TGFBeta Induced HIV-1 Restriction in Langerhans cells 
MA Czubala, M Ivory, Z Ahmed, F Blanchet and V Piguet Infection and Immunity, Cardiff 
University, Cardiff, United Kingdom
Our study aims to decipher restrictions of HIV-1 infection in Langerhan cells (LC). For this purpose 
we employed two LC cell models, monocytes derived LC and MUTZ-3 derived LC, as well as 
primary Langerhan cells freshly isolated from skin explants. We show that SAMHD1 is expressed 
in LCs but in contrast to myeloid DCs, the degradation mediated by Vpx did not result in rescue 
of HIV-1 infection in LCs models. Importantly, Vpx-mediated degradation of SAMHD1 in dermal 
DCs freshly isolated from human skin led to a strong increase of HIV-1 replication. On the con-
trary, down-regulation of SAMHD1 expression in skin-derived LCs did not result in a statistically 
significant enhancement of HIV-1 infection. The restriction activity in LCs was induced by TGF-β 
and was present in immature LCs at a steady-state. Additionally, maturation of LC with bacteria 
components diminished LC restrictive phenotype, which explains why HIV acquisition is increased 
during co-infection. In conclusion, we report a novel TGF-β-dependent HIV-1 post-entry restriction 
activity, which is specifically present in immature LCs and potently protects these cells from HIV-1 
infection. Modulating or enhancing this natural resistance of LCs to HIV-1 infection may offer novel 
avenues to block HIV-1 in its early stages of transmission.    
   
